Exhaled nitric oxide is associated with inflammatory biomarkers and risk of acute respiratory exacerbations in children with HIV-associated chronic lung disease
dc.contributor.author | Flygel, Trym Thune | |
dc.contributor.author | Hameiri-Bowen, Dan | |
dc.contributor.author | Simms, Victoria | |
dc.contributor.author | Rowland-Jones, Sarah | |
dc.contributor.author | Ferrand, Rashida Abbas | |
dc.contributor.author | Bandason, Tsitsi | |
dc.contributor.author | Yindom, Louis-Marie | |
dc.contributor.author | Odland, Jon Oyvind | |
dc.contributor.author | Cavanagh, Jorunn Pauline | |
dc.contributor.author | Flaegstad, Trond | |
dc.contributor.author | Sovershaeva, Evgeniya | |
dc.date.accessioned | 2024-04-11T07:37:53Z | |
dc.date.available | 2024-04-11T07:37:53Z | |
dc.date.issued | 2024-02 | |
dc.description | SUPPORTING INFORMATION : FIGURE S1. Box plot of eNO at baseline and 48 weeks by trial group and overall. AZM, azithromycin; eNO, exhaled nitric oxide. TABLE S1. Baseline characteristics of participants by trial group. TABLE S2. Effect of azithromycin on levels of eNO after 48 weeks of treatment using a generalized linear model. eNO, exhaled nitric oxide. | en_US |
dc.description.abstract | OBJECTIVES : Chronic lung disease is a recognized complication in children with HIV. Acute respiratory exacerbations (ARE) are common among this group and cause significant morbidity. Exhaled nitric oxide (eNO) is a known marker of local airway inflammation. We investigated the association between eNO and ARE, biomarkers of systemic inflammation, and the effect of azithromycin on eNO levels. METHODS : Individuals aged 6–19 years with HIV-associated chronic lung disease in Harare, Zimbabwe, were enrolled in a placebo-controlled randomized trial investigating the effect of 48-week azithromycin treatment on lung function and ARE. eNO levels and biomarkers were measured at inclusion and after treatment in a consecutively enrolled subset of participants. Linear regression and generalized linear models were used to study associations between eNO and ARE, biomarkers, and the effect of azithromycin on eNO levels. RESULTS : In total, 172 participants were included in this sub-study, 86 from the placebo group and 86 from the azithromycin group. Participants experiencing at least one ARE during follow-up had significantly higher eNO levels at baseline than participants who did not (geometric mean ratio 1.13, 95% confidence interval [CI] 1.03–1.24, p = 0.015), adjusted for trial arm, age, sex and history of tuberculosis. Matrix metalloproteinase (MMP)-3, -7, and -10 were significantly associated with higher baseline eNO levels. At 48 weeks, azithromycin treatment did not affect eNO levels (geometric mean ratio 0.86, 95% CI 0.72–1.03, p = 0.103). CONCLUSION : Higher baseline eNO levels were a risk factor for ARE. eNO was associated with proinflammatory biomarkers previously found to contribute to the development of chronic lung disease. The potential use of eNO as a marker of inflammation and risk factor for ARE in HIV-associated chronic lung disease needs further investigation. | en_US |
dc.description.department | School of Health Systems and Public Health (SHSPH) | en_US |
dc.description.librarian | hj2024 | en_US |
dc.description.sdg | SDG-03:Good heatlh and well-being | en_US |
dc.description.sponsorship | Norges Forskningsråd; Global Health and Vaccination Research (GLOBVAC) programme; Helse Nord RHF; Wellcome Trust PhD Programme in Genomic Medicine and Statistics; Wellcome Trust; UK Medical Research Council; UK Department for International Development (DFID); European Union. | en_US |
dc.description.uri | http://wileyonlinelibrary.com/journal/hiv | en_US |
dc.identifier.citation | Flygel, T.T., Hameiri-Bowen, D., Simms, V., et al. Exhaled nitric oxide is associated with inflammatory biomarkers and risk of acute respiratory exacerbations in children with HIV-associated chronic lung disease. HIV Medicine 2024; 25(2): 223‐232. doi:10.1111/hiv.13565. | en_US |
dc.identifier.issn | 1464-2662 (print) | |
dc.identifier.issn | 1468-1293 (online) | |
dc.identifier.other | 10.1111/hiv.13565 | |
dc.identifier.uri | http://hdl.handle.net/2263/95478 | |
dc.language.iso | en | en_US |
dc.publisher | Wiley | en_US |
dc.rights | © 2023 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association. This is an open access article under the terms of the Creative Commons Attribution License. | en_US |
dc.subject | Africa | en_US |
dc.subject | Biomarkers | en_US |
dc.subject | Chronic lung disease | en_US |
dc.subject | Human immunodeficiency virus (HIV) | en_US |
dc.subject | Inflammation | en_US |
dc.subject | Acute respiratory exacerbations (ARE) | en_US |
dc.subject | Exhaled nitric oxide (eNO) | en_US |
dc.subject | SDG-03: Good health and well-being | en_US |
dc.title | Exhaled nitric oxide is associated with inflammatory biomarkers and risk of acute respiratory exacerbations in children with HIV-associated chronic lung disease | en_US |
dc.type | Article | en_US |
Files
Original bundle
1 - 4 of 4
Loading...
- Name:
- Flygel_Exhaled_2023.pdf
- Size:
- 699.61 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article
Loading...
- Name:
- Flygel_ExhaledFigS1_2023.pdf
- Size:
- 80.05 KB
- Format:
- Adobe Portable Document Format
- Description:
- Figure S1
Loading...
- Name:
- Flygel_ExhaledTabS1_2023.pdf
- Size:
- 136.65 KB
- Format:
- Adobe Portable Document Format
- Description:
- Table S1
Loading...
- Name:
- Flygel_ExhaledTabS2_2023.pdf
- Size:
- 61.36 KB
- Format:
- Adobe Portable Document Format
- Description:
- Table S2
License bundle
1 - 1 of 1
Loading...
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: